Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

UPDATE Exposed: Aeras’ Upcoming Film Series on Tuberculosis

exposed

Release of Part 1 of EXPOSED scheduled for the week of May 20. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will portray the struggles of four inspiring individuals – an MDR-TB survivor, a TB doctor, a clinical trial volunteer, and a TB vaccine researcher – bringing viewers to the forefront of the race against tuberculosis.

26 Apr 2013
by Working Group

Posted in Announcements, TB Drug Development, TB Pediatrics

Tagline Spring 2013: 3 Articles on TB Research

taglogo

Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access, 2) on adaptive clinical trial designs, and 3) on pediatric drug development needs.

TB Edition of The Lancet Infectious Diseases

Click to access links and audio from Lancet ID TB Edition

To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO.

FDA Advisory Committee recommends Janssen’s Bedaquiline for accelerated approval

FDA-Logo1

Yesterday, Nov. 28th, the FDA Ant-infective Drug Advisory Committee voted to recommend Janssen’s Bedaquiline for accelerated approval for the treatment of MDR tuberculosis. A summary of the proceedings is included.

Immunotherapeutic Vaccines, TB and China: Interview with Dr. Douglas Lowrie

thumb206-lowrie

This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.

4 Sep 2012
by Working Group

Posted in Front Lines of TB R&D, TB News, TB Treatment

TB R&D Weekly Update: High Dose Vitamin D May Enhance TB Treatment

pnas35.cover

This week we highlight a study showing promising results that providing high dose vitamin D supplements along with antibiotics could improve treatment outcomes for TB patients. The abstract and additional news coverage are included, as well as, links to other TB R&D news.

29 Aug 2012

Live Streaming of Demystifying Pyrazinamide Workshop–September 5 & 6

Pyrazinamide_Structure

On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS Research, and the Stop TB Partnership Working Group on New Drugs. There will be live streaming available.

15 Aug 2012

2012 WGND Annual Meeting is Nov 14 in Kuala Lumpur

2010 Annual Meeting

We will have our 2012 Annual Meeting in Kuala, Lumpur on Wednesday, November 14 at the Impiana KLCC Hotel from 13:00 to 17:30. The meeting will be held in conjunction with the 43rd Union World Conference on Lung Health.

24 Jul 2012
by Working Group

Posted in Announcements, TB Drug Development, TB News, Video

TB R&D Weekly Update: Results from First Novel Regimen Trial Published

novel regimen video

Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Link to article, press release, and related video are included. Additional links to TB R&D news are also included.

5 Jul 2012
by Working Group

Posted in Announcements, TB Drug Development, TB News

TB R&D Weekly Update: Janssen Seeks Approval from FDA for Bedaquiline

janssen2

This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207).